Feedback
We’d love to hear your feedback on this activity. It helps us to continually improve our products.
CORRECT!
Faculty & Disclosures
Dr Toni Choueiri
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Dr Toni Choueiri is the director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute (DFCI), co-leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center, and the Jerome and Nancy Professor of Medicine at Harvard Medical School. He is the medical director of International Strategic Initiatives at DFCI and past president of the Medical Staff at DFCI (2016–2018). read more
Dr Choueiri is interested in developing novel experimental therapies and biomarkers in GU malignancies, including renal cell carcinoma (RCC). In a series of New England Journal of Medicine articles, Dr Choueiri and colleagues have made seminal observations that have defined and evolved the treatment of metastatic RCC and led to the approval of several therapies such as cabozantinib, pazopanib, avelumab + axitinib, cabozantinib + nivolumab, pembrolizumab + lenvatinib, and adjuvant pembrolizumab. His research also focuses on the epidemiology, diagnosis and treatment outcomes of GU cancers, especially through having co-established the International Metastatic RCC Database Consortium criteria for RCC risk stratification. His biomarker work has shed light on complex immunogenomics mechanisms contributing to response and resistance to targeted therapy and immunotherapy.Â
He received the George Canellos Award for Excellence in Clinical Investigation and Patient Care from DFCI in 2013, the Eugene Schonfeld Award from the Kidney Cancer Association in 2016, and is a 2021 Giants of Cancer Care inductee. He serves on the National Comprehensive Cancer Network Kidney Cancer Panel, KidneyCan Board and the National Cancer Institute GU steering committee.Â
Dr Choueiri’s work has been published in journals such as the New England Journal of Medicine, Journal of American Medical Association (JAMA), JAMA Oncology, The Lancet, Lancet Oncology and Journal of Clinical Oncology.Â
He lectures frequently around the world and has over 675 PubMed-indexed publications on GU cancers.
Dr Toni Choueiri discloses: Advisory board/Panel and Consultancy fees and Grants/Research support from Aravive, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Calithera, Circle Pharma, Eisai, EMD Serono, Exelixis, GlaxoSmithKline, Infinity, Ipsen, Janssen, Kanaph, Lilly, Merck, Nikang, Novartis, Pfizer, Roche, Sanofi-Aventis, Surface Oncology, Takeda and Tempest Therapeutics. Stock/Shareholder (self-managed) Osel, Pionyr and Tempest Therapeutics.
Dr Cristina Suárez
Vall d´Hebron University Hospital, Barcelona, Spain
Dr Cristina Suárez is a medical oncologist at the Vall d´Hebron University Hospital in Barcelona, Spain. read more
Dr Suárez received her MD in Medicine and Surgery at the Autonomous University of Barcelona. She received specialist training in medical oncology at the Faculty of Medicine, Autonomous University of Barcelona and Hospital del Mar – Parc de Salut, Barcelona. In 2008, she joined the Oncology Department at Vall d’Hebron University Hospital as a physician (attending staff) in the Genitourinary, Central Nervous System, Sarcoma and Tumours of Unknown Origin Program.
In 2018, Dr Suárez obtained her cum laude qualification when she completed her doctorate studies with the doctoral thesis: ‘Prognostic value of genetic alterations in the mTOR pathway of patients with metastatic renal cell carcinoma treated with mTOR inhibitors’.
She has been co-investigator and principal investigator in several clinical trials related to genitourinary malignancies, and is the author or co-author of more than 100 scientific papers, posters and book chapters focused on the area of genitourinary tumours.
She is vice president of SOGUG (Spanish Oncology Genitourinary Group), an active member of several oncology societies such as ASCO, ESMO, SEOM and SOGUG, and a scientific committee member of ASCO and ESMO.
Dr Cristina Suárez discloses: Advisory board/Panel and Consultancy fees from Astellas, Bayer, Bristol Myers Squibb, Ipsen, Merck & Co, Inc. (MSD), Pfizer, Roche and Sanofi. Grants/Research support from Ipsen. Speaker’s Bureau fees from Astellas, Bristol Myers Squibb, Ipsen, Pfizer and Roche.
